Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Venetoclax plus rituximab or obinutuzumab in CLL after alloHCT

Othman Al-Sawaf • 20 Jun 2019
ICML 2019
Chronic Lymphocytic Leukemia Leukemia Obinutuzumab Rituximab Venetoclax

Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, discusses the use of venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL). This was taken from the clinical data of 4 patients at his center, indicating that treatment with venetoclax is feasible and effective in patients with CLL and relapsed disease after alloHCT. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Othman Al-Sawaf

1:47
Treatment of Richter’s transformation: recent insights
Othman Al-Sawaf • 16 Jun 2023
1:26
The expanding landscape of next-generation BTK inhibitors in CLL
Othman Al-Sawaf • 16 Jun 2023
0:56
Fixed-duration treatment strategies for frontline and relapsed CLL
Othman Al-Sawaf • 16 Jun 2023
1:43
Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL
Othman Al-Sawaf • 16 Jun 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals